Related Experiment Video
Updated: Aug 5, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Pulmonary Hypertension in a 19-Year-Old Patient Due to a Mutation in the Bone Morphogenetic Protein Receptor Gene: A
Federico Pelloni1, Maria Luisa De Perna1, Giorgio Moschovitis1
1Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, CHE.
Abstract:
Pulmonary hypertension (PH) is a chronic disease with a high socio-economic and health burden, often misdiagnosed or diagnosed late due to the absence of specific symptoms, with often fatal outcomes. Despite numerous studies on the disorder, the exact mechanisms of onset are not yet fully understood, and the therapeutic possibilities, although increasing, are still few and not curative. We report the case of an apparently healthy 19-year-old woman who presented with recurrent syncope, dyspnea, and chest pain on exertion. Diagnostic work-up showed severe PH, and genetic analysis revealed a truncating mutation in the bone morphogenetic protein receptor gene 2 as an etiologic factor. Similar mutations in the same gene, inherited in an autosomal-dominant pattern, are already known as the causative factor of PH. Despite the implementation of guideline-directed medical therapy, the clinical situation rapidly deteriorated, and the patient died due to a pulmonary hemorrhage. This case report highlights the importance of early diagnosis, especially at a young age, and the need for treatment by a center specialized in these disorders.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Abnormal Proliferation

